Leongamornlert, Daniel;
Gutiérrez-Abril, Jesús;
Lee, Soo Wah;
Barretta, Emilio;
Creasey, Tom;
Gundem, Gunes;
Levine, Max Fine;
... Papaemmanuil, Elli; + view all
(2023)
Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia.
Blood Advances
10.1182/bloodadvances.2022008992.
(In press).
Preview |
Text
Fielding_bloodadvances.2022008992.pdf Download (5MB) | Preview |
Abstract
Genomic profiling at diagnosis of B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL) in adults is used to guide disease classification, risk stratification and treatment decisions. Patients for which diagnostic screening fails to identify disease defining or risk stratifying lesions are classified as B-other ALL. We screened a cohort of 652 BCP-ALL cases enrolled in UKALL14 to identify and perform whole genome sequencing (WGS) on paired tumor-normal samples. For 52 B-other patients we compared WGS findings to data from clinical and research cytogenetics. WGS identifies a cancer associated event in 51/52 cases, this includes an established subtype defining genetic alteration in 5/52 that were previously missed by standard-of-care genetics. Of the 47 true B-other ALL we identified a recurrent driver in 87% (41). Complex karyotype by cytogenetics emerges as a heterogeneous group, including distinct genetic alterations associated with either favorable (DUX4-r) or poor outcomes (MEF2D-r, IGK::BCL2). For a subset of 31 cases, we integrate findings from RNA-sequencing (RNA-seq) analysis to include fusion gene detection, and classification by gene expression. Compared to RNA-seq, WGS was sufficient to detect and resolve recurrent genetic subtypes, however RNA-seq can provide orthogonal validation of findings. In conclusion, we demonstrate that WGS can identify clinically relevant genetic abnormalities missed by standard-of-care testing and identify leukemia driver events in virtually all cases of B-other ALL.
Archive Staff Only
 |
View Item |
